Research Article

A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study

Table 1

Demographic and baseline clinical characteristics.

Parameters

Age (yr), mean (SD)39.39 (15.82)
Sex
Male, n (%)35 (33.3)
Female, n (%)70 (66.7)
BMI, mean (SD)24.57 (2.7)

Comorbidity
At least one comorbidity, n (%)44 (41.9)
Smoking, n (%)3 (2.9)
Addiction1 (0.9)
DM, n (%)9 (8.6)
HTN, n (%)11 (10.5)
DLP, n (%)10 (9.5)
IHD, n (%)2 (1.9)
Thyroid disorder, n (%)8 (7.6)
Depression, n (%)2 (1.9)
Asthma, n (%)6 (5.7)
Sinusitis, n(%)3 (2.8)
IBD, n (%)2 (1.9)
Allergy history, n (%)10 (9.5)
AD, n (%)1 (0.9)

Clinical symptoms
Fever, n (%)37 (35.2)
Sore throat, n (%)71 (67.6)
Cough, n (%)63 (60)
Chest pain, n (%)35 (33.3)
Dyspnea, n (%)42 (40)
Runny nose, n (%)7 (6.7)
Fatigue, n (%)82 (78.1)
Headache, n (%)53 (50.5)
Myalgia, n (%)58 (55.2)
Vertigo, n (%)16 (15.2)
Dyspepsia, n (%)5 (17)
Diarrhea, n (%)25 (23.8)
Nausea, n (%)12 (11.4)
Loss of appetite, n (%)41 (39)
Anosmia, n (%)36 (34.3)
Ageusia, n (%)32 (30.5)
Excessive sweeting, n (%)12 (11.4)
Skin rash, n (%)5 (4.8)
Red eyes, n (%)4 (3.8)

COVID-19 data
COVID-19 contact history
Travel history, n (%)2 (1.9)
Family member, n (%)26 (24.8)
Attending a party, n (%)8 (7.6)
Unknown, n (%)69 (65.7)

COVID-19 confirmation
Lung CT scan involvement, n (%)105 (100)
RT-PCR, n (%)41 (39)

BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; DLP: dyslipidemia; IHD: ischemic heart disease; IBD: irritable bowel disease; AD: Alzheimer disease; RT-PCR: reverse transcription polymerase chain reaction; CT: computerized tomography.